At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specific...

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC...

Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing...

Panelists discuss how early recognition of Dravet syndrome's key clinical features—including prolonged seizures triggered by fever or illness in the f...

Panelists discuss how SCN1A genetic testing has enabled earlier diagnosis of Dravet syndrome, though some clinicians still hesitate to order tests due...

Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clini...

Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets...

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alexa Dessy, MD. [LISTEN TIME: 17 minutes]

The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’...